Bladder carcinoma in situ (CIS) in Australia: A rising incidence for an under-reported malignancy

BJU International

Volumn 112, Issue SUPPL. 2, 2013, Pages 46-52

  Ranasinghe, Weranja K B ^a   Attia, John ^b   Oldmeadow, Christopher ^b   Lawrentschuk, Nathan ^a,c   Robertson, Jane ^b   Ranasinghe, Tamra ^d   Bolton, Damien ^a   Persad, Raj ^e  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d MAYO CLINIC   (United States)

^e BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Australia; Bladder carcinoma; Carcinoma in situ

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; BLADDER CARCINOMA; BLADDER CARCINOMA IN SITU; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER REGISTRY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREND STUDY; AGE; BIOPSY; BLADDER TUMOR; CARCINOMA IN SITU; ENDOSCOPY; INCIDENCE; MIDDLE AGED; REGISTER; RISK FACTOR; TRANSURETHRAL RESECTION; VERY ELDERLY; URINARY BLADDER NEOPLASMS;

AUSTRALIA; BLADDER CARCINOMA; CARCINOMA IN SITU;

AGE FACTORS; AGED; AGED, 80 AND OVER; AUSTRALIA; BIOPSY; CARCINOMA IN SITU; ENDOSCOPY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; URINARY BLADDER NEOPLASMS;

EID: 84891544591     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12052     Document Type: Article

References (21)

1. Ferlay JSH, Bray F, Forman D, Mathers C Parkin DM. GLOBOCAN 2008, Cancer Incidence and MortalityWorldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010 [cited 2010 July]. Available at: http://globocan.iarc.fr. Accessed January 2013
2. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218: 12-20
3. Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27: 295-300
4. Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 2004; 45: 142-6
5. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994; 157: 147-51
6. LammDL.Carcinoma in situ. Urol Clin North Am 1992; 19: 499-508
7. Statistics ABo. Australian Bureau of statistics website [cited May 2011]. Available at: http://www.abs.gov.au/ausstats/abs.nsf/mf/4831.0.55.001/. Accessed January 2013
8. CheReL. Quality of Routinely Collected Data represented in the CHeReL Master Linkage Key. CheReL database; April 2009 [cited 2012]. Available at: http://www.cherel.org.au/media/13588/validation-studies-april-2009.pdf. Accessed January 2013
9. Luke C, Tracey E, Stapleton A, Roder D. Exploring contrary trends in bladder cancer incidence, mortality and survival: implications for research and cancer control. Intern Med J 2010; 40: 357-62
10. Cheng L, Cheville JC, Neumann RM et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469-74
11. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995; 153: 564-72
12. Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 2010; 76: 112-26
13. Duncombe J, Stavrou E, Chen W, Baker D, Tracey E, Bishop, JF. Bladder Cancer in New South Wales, February 2009. Cancer Institute NSW Monograph. Available at: 2009-02-bladder-cancer-in-nsw.pdf. Acessed January 2013
14. NSW CI. Online statistics Module - NSW Central Cancer Registry. Cancer Institute NSW; 2011 [cited 2011 November]. Available at: http://www. cancerinstitute.org.au/data-and-statistics/cancer-statistics/online-statistics module. Accessed January 2013
15. Malmstrom PU, Sylvester RJ, Crawford DE et al. An individual patient data meta analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56
16. van der Meijden AP, Sylvester R, Oosterlinck W et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005; 48: 363-71
17. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002; 167: 2408-12
18. Medicare-Australia. Pharmaceutial Benefits scheme- Requested PBS & RPBS Items (no. 1140B) processed from January 1992 to August 2011. Tuggeranong ACT Available at: statistics/pbs-item.shtml. Accessed January 2013
19. Steiner H, Bergmeister M, Verdorfer I et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int 2008; 102: 291-6
20. Ferra S, Denley R, Herr H, Dalbagni G, Jhanwar S, Lin O. Reflex UroVysion testing in suspicious urine cytology cases. Cancer 2009; 117: 7-14
21. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008